You are here

  • Home
  • Archive
  • Volume 29, Issue Suppl 1
  • 2SPD-005 Significant discontinuation rates in patients initiating or switching from CT-P13: a retrospective cohort study in a university hospital

Article Text

Article menu

Download PDFPDF

Section 2: Selection, procurement and distribution
2SPD-005 Significant discontinuation rates in patients initiating or switching from CT-P13: a retrospective cohort study in a university hospital
Free
  1. M Krstic1,2,3,4,
  2. JC Devaud2,3,
  3. J Marti5,6,
  4. F Sadeghipour1,2,3,4
  1. 1Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva and University of Lausanne, Pharmaceutical Sciences, Geneva and Lausanne, Switzerland
  2. 2Service of Pharmacy, Lausanne University Hospital and University of Lausanne, Pharmacy, Lausanne, Switzerland
  3. 3Centre for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, Pharmacy, Lausanne, Switzerland
  4. 4School of Pharmaceutical Sciences, University of Geneva, Pharmaceutical Sciences, Geneva, Switzerland
  5. 5University of Lausanne, Faculty of Biology and Medicine, Lausanne, Switzerland
  6. 6University of Lausanne, Centre for Primary Care and Public Health Unisanté, Lausanne, Switzerland

Abstract

Background and importance CT-P13 is an infliximab biosimilar that received market authorisation in the European Union in 2013. CT-P13 has undeniable cost-saving opportunities and extensive literature supporting its equivalence to originator infliximab (OI) in terms of efficacy, safety and immunogenicity. Despite these elements, CT-P13 remains largely underused in our country, either underprescribed or discontinued after its introduction.

Aim and objectives The aim of this study was to explore the reasons behind the high discontinuation rate observed among the patients on CT-P13 in a large tertiary hospital.

Material and methods A retrospective cohort study using routinely collected data was carried out. Patients were eligible if they received OI or CT-P13 between September 2017 and December 2020. They were included if they had received at least two CT-P13 infusions during the same period. Patients were excluded if their medical history was incomplete prior to or 6 months after their first CT-P13 infusion and if they had an oncological main diagnosis.

Results 156 patients were included and classified into two groups: switchers that were treated with OI and were switched to CT-P13 (n = 85, 54%) and initiators that did not receive OI prior to CT-P13 treatment (n = 71, 46%). 23 (27%) switchers and 35 (49%) initiators discontinued CT-P13 after 12 months. Main reasons for CT-P13 discontinuation were lack of efficacy (n = 21, 36%) and secondary loss of response (n = 16, 28%). Lack of active training and coordination among healthcare professionals and little patient education may have exacerbated patients’ subjective complaints and increased the CT-P13 discontinuation rate.

Conclusion and relevance Lack of efficacy and secondary loss of response were the main reasons for the high CT-P13 discontinuation rate observed in a large tertiary hospital. Coordination between the various healthcare professionals involved with the patients is a prerequisite for biosimilars to achieve their maximum cost-saving potential.

Conflict of interest No conflict of interest

https://doi.org/10.1136/ejhpharm-2022-eahp.11

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.